Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: drug prices

Costly Drugs to Weigh on U.S. Employers’ Expenses in 2018

Divya Grover  |  

(Reuters)—U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases, such as cancer, multiple sclerosis and hepatitis C, is expected to rise more than 7%, according to consultancy firm Mercer.1 Between 40 and 50 new specialty drugs are set to hit the market each year in…

Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears

Deena Beasley  |  

(Reuters)—As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation’s first law designed to punish drugmaker price-gouging. The Maryland Attorney General’s office said it will field complaints and investigate “unconscionable increases” in essential generic medicines when the closely watched law takes effect Oct….

Doctors Who Take Pharmaceutical Money Use Twitter to Hype Drugs

Ronnie Cohen  |  

(Reuters Health)—Some cancer doctors use Twitter to promote drugs manufactured by companies that pay them, but they almost never disclose their conflicts of interest on the social media platform, a new study shows. “This is a big problem,” says senior author Dr. Vinay Prasad, a professor at Oregon Health and Science University in Portland. “Doctors…

U.S. Tribal Patent Deal Could Impact Generic Drug Market

Jan Wolfe  |  

(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

Diane Bartz  |  

WASHINGTON (Reuters)—Republican and Democratic lawmakers on Thursday discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines. The focus at a hearing, held by members of the House Judiciary Committee’s antitrust subcommittee, was on the use by some brand name drug companies of a U.S….

Generic Drug Group Sues to Block Maryland Price-Gouging Law

Nate Raymond  |  

(Reuters)—The main U.S. trade group for generic pharmaceutical companies filed a lawsuit on Thursday seeking to block a recently adopted Maryland law that lets the state attorney general sue generic drugmakers that sharply raise prices. The Association for Accessible Medicines filed the lawsuit in federal court in Baltimore to seek an injunction that would block…

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

  |  

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

Andrew Chung  |  

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9–0 ruling, overturned a lower court…

Valeant Prices Psoriasis Treatment at $3,500 Per Month

Reuters Staff  |  

(Reuters)—Canadian drug maker Valeant Pharmaceuticals International Inc. said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Brodalumab (Siliq) is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant says. Drugmakers are facing intense criticism from…

Maryland Lawmakers Approve Bill to Fight Drug Price-Gouging

Ian Simpson  |  

WASHINGTON (Reuters)—Maryland lawmakers have passed a first-in-the-nation measure that lets the state attorney general sue generic drugmakers that sharply raise prices in a move aimed at fighting what legislators call “price-gouging.” The bill overwhelmingly was approved by the Democratic-controlled legislature on Monday and hailed by Maryland Attorney General Brian Frosh as a way to check…